Clinical trials: Risk of Cardiac Arrhythmias
Atrial Fibrillation
Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation
This study is being done to see if the addition of mangosteen juice to standard medical care will reduce the risk of atrial fibrillation (AF) recurrence following direct current (DC) cardioversion.
- Trial name
- MRI-AF (NCT00951301)
- Testing
- mangosteen juice
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Mayo Clinic
Brugada Syndrome, Cardiac Arrest
Feasibility of Improving Risk Stratification in Brugada Syndrome
Feasibility of Improving Risk Stratification in Brugada Syndrome (BrS), retrospective cohort study To study the reproducibility and specificity of V-CoS for activation heterogeneities predisposing to VT/VF in a larger series of…
- Conditions
- Brugada Syndrome, Cardiac Arrest, Athletes Heart, Atrial Fibrillation
- Trial name
- FIRST-BrS (NCT03992677)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Heart Failure, Coronary Heart Disease (CHD)
Reliability of Multiple-Repetition-Maximum Tests in Patients With Cardiovascular Disease or Risk Factors
Exercise training is a cornerstone in the prevention and rehabilitation of cardiovascular disease. While research has primarily focused on endurance training, resistance training becomes more and more important.
- Conditions
- Heart Failure, Coronary Heart Disease (CHD), Atrial Fibrillation (AF), Diabetes Mellitus
- Trial name
- NCT06796582
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Technical University of Munich
Atrial Fibrillation, Bleeding
Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics
Objectives: Atrial fibrillation (AF) is the most common arrhythmia. Anticoagulation with warfarin or new oral anticoagulants in patients with AF can significantly reduce thromboembolic events.
- Conditions
- Atrial Fibrillation, Bleeding, Anticoagulant Therapy
- Trial name
- NCT05181774
- Testing
- Proteomics, Metabolomics
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yue LI
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Patent Foramen Ovale, Atrial Arrhythmia
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
About 30% of ischemic strokes are cryptogenic. Patent Foramen Ovale (PFO) is present in about 25% of the general population. In cryptogenic strokes, PFO has been shown to be overrepresented and recent intervention studies have…
- Conditions
- Patent Foramen Ovale, Atrial Arrhythmia, Cryptogenic Stroke
- Trial name
- AFLOAT (NCT05213104)
- Testing
- Flecainide
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Stroke, Atrial Fibrillation
B2AD-Risk AFDAS Evolution of Burden of AF
Each year, 7.8 million people worldwide experience an ischemic stroke, often caused by atrial fibrillation (AF). AF is a major contributor to severe, disabling, and deadly strokes.
- Trial name
- B2AD-Risk AF (NCT06589700)
- Testing
- Implantable Loop Recorder
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Luciano A. Sposato
Atrial Fibrillation (AF), Atrial Fibrillation New Onset
Clinical Validation of SMD-AFECG for Predicting New-Onset Atrial Fibrillation Within 2 Hours Using Single-Lead ECG Data
The purpose of this retrospective study is to evaluate the clinical performance of SMD-AFECG, an artificial intelligence-based medical device software that predicts the risk of atrial fibrillation occurring within 2 hours using…
- Trial name
- NCT07722078
- Volunteers
- 797 people
- Sponsor
- HUINNO Co., Ltd
Thromboprophylaxis, Thromboembolism, Venous
Thromboembolic Risk Assessment in Patients Admitted With Acute Medical Diseases to Conventional and At Home Hospitalization
The thromboembolic disease is a common complication of patients admitted to conventional hospitalization units. To prevent such complications, thromboprophylaxis is indicated in high-risk patients identified with validated…
- Conditions
- Thromboprophylaxis, Thromboembolism, Venous, Atrial Fibrillation, Physical Inactivity
- Trial name
- TROMBODOM (NCT06110949)
- Testing
- Triaxial accelerometry
- Where
- Spain
- Volunteers
- 1,953 people
- Sponsor
- Universidad Pública de Navarra
Atrial Fibrillation New Onset
Diagnostic Validation of Wearable ECG Monitoring Patch, ATP-C120
A new wearable patch-type device, ATP-C120 (ATsens, Seongnam, Korea) is a novel, single-lead ECG monitoring device and can continuously monitor the ECG signal for upto 11 days.
- Trial name
- NCT04857268
- Testing
- wearable continuous ECG monitoring patch, ATP-C120
- Where
- 2 sites in South Korea
- Volunteers
- 320 people
- Sponsor
- Seoul National University Bundang Hospital
Defibrillators, Implantable, Myocardial Infarction
Risk of Life-threatening Heart Rhythm Disturbances in Siblings
The purpose of this study is to determine if heredity influences the risk of life-threatening heart rhythms (ventricular tachycardia and ventricular fibrillation) after heart attack (myocardial infarction).
- Conditions
- Defibrillators, Implantable, Myocardial Infarction, Tachycardias, Ventricular
- Trial name
- SIBFIB (NCT00498524)
- Testing
- ICD
- Where
- United States
- Volunteers
- 2,047 people
- Sponsor
- Duke University
Insulin Treated Type 2 Diabetes With High Risk of Hypoglycemia
Efficacy of Flash Glucose-Sensing Technology on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia
Hypoglycemia, frequently asymptomatic, may lead to cardiac arrythmias and induce an increased risk of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D).
- Trial name
- NCT03570138
- Testing
- FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System, Usual self monitoring Blood Glucose device
- Where
- 7 sites in France
- Volunteers
- 200 people
- Sponsor
- Poitiers University Hospital
Ischemic Heart Disease, Atrial Fibrillation
Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients
Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.
- Trial name
- INTERMITTENT (NCT04151680)
- Testing
- Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban, Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Fibrillation, Atrial
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
- Trial name
- NOAC (NCT06874894)
- Where
- 2 sites in South Korea
- Volunteers
- 1,021 people
- Sponsor
- Chung-Ang University Hospital
Pacemaker DDD, Atrioventricular Block
Risk of Pacing-induced Cardiomyopathy
This study will evaluate the association between right ventricular pacing and the risk of pacing-induced cardiomyopathy.
- Conditions
- Pacemaker DDD, Atrioventricular Block, Pacing-Induced Cardiomyopathy
- Trial name
- NCT04269733
- Testing
- Right ventricular pacing
- Where
- Denmark
- Volunteers
- 153 people
- Sponsor
- Aalborg University Hospital
Atrial Fibrillation
Assessing the Safety and Efficacy of the LAmbre™ Plus Device
Randomized controlled trial assessing the safety and efficacy of the LAmbre Plus LAA Closure System to rescue the risk of thromboembolism in patients with non-valvular AF.
- Trial name
- REDUCE-AF (NCT06465706)
- Testing
- LAmbre investigational device
- Volunteers
- 1,826 people
- Sponsor
- Kansas City Heart Rhythm Research Foundation
Ventricular Arrythmia, Right Ventricular Dysfunction
Cardiovascular Consequences in Intense and Extended Physical Exercise
This research study because you participate in long distance triathlon of Embrun. In recent years, there has been a craze for races at increasingly longer distances (ultra-endurance) with risks to the cardiovascular system poorly…
- Trial name
- PHILIPPIDES (NCT03972865)
- Testing
- EmbrunMan race
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Atrial Fibrillation, Thromboembolism
Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
The purpose of this study is to investigate the appropriate duration of dabigatran use after radiofrequency catheter ablation for paroxysmal atrial fibrillation in patients with low thromboembolic risk.
- Trial name
- NCT02313584
- Testing
- dabigatran
- Volunteers
- 464 people
- Sponsor
- Korea University
Atrial Fibrillation
Risk Profile for Atrial Fibrillation
The objective of this study is to assess the risk profile in patients with atrial fibrillation, which represents the degree of changes (remodeling) in the atrial tissue and which can help to predict in which patients rhythm…
- Trial name
- NCT01510197
- Where
- Netherlands
- Volunteers
- 503 people
- Sponsor
- University Medical Center Groningen
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc